118 related articles for article (PubMed ID: 38697311)
1. Calcium saccharate/DUSP6 suppresses renal cell carcinoma glycolytic metabolism and boosts sunitinib efficacy via the ERK-AKT pathway.
Liu H; Wang L; Shi X; Yin L; Zhai W; Gao S; Chen Y; Zhang T
Biochem Pharmacol; 2024 Jun; 224():116247. PubMed ID: 38697311
[TBL] [Abstract][Full Text] [Related]
2. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
3. Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis.
Duan S; Moro L; Qu R; Simoneschi D; Cho H; Jiang S; Zhao H; Chang Q; de Stanchina E; Arbini AA; Pagano M
Cell Rep; 2021 Oct; 37(3):109870. PubMed ID: 34686346
[TBL] [Abstract][Full Text] [Related]
4. Splice variants of lysosome‑associated membrane proteins 2A and 2B are involved in sunitinib resistance in human renal cell carcinoma cells.
Nishikawa R; Osaki M; Sasaki R; Ishikawa M; Yumioka T; Yamaguchi N; Iwamoto H; Honda M; Kabuta T; Takenaka A; Okada F
Oncol Rep; 2020 Nov; 44(5):1810-1820. PubMed ID: 32901843
[TBL] [Abstract][Full Text] [Related]
5. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.
Zhao T; Bao Y; Gan X; Wang J; Chen Q; Dai Z; Liu B; Wang A; Sun S; Yang F; Wang L
Theranostics; 2019; 9(21):6175-6190. PubMed ID: 31534544
[No Abstract] [Full Text] [Related]
7. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
D'Amato C; Rosa R; Marciano R; D'Amato V; Formisano L; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fulciniti F; Cipolletta A; Bianco C; Ciardiello F; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Sep; 111(6):1168-79. PubMed ID: 25093491
[TBL] [Abstract][Full Text] [Related]
9. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
[No Abstract] [Full Text] [Related]
10. NT5E inhibition suppresses the growth of sunitinib-resistant cells and EMT course and AKT/GSK-3β signaling pathway in renal cell cancer.
Peng D; Hu Z; Wei X; Ke X; Shen Y; Zeng X
IUBMB Life; 2019 Jan; 71(1):113-124. PubMed ID: 30281919
[TBL] [Abstract][Full Text] [Related]
11. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway.
Lin A; Piao HL; Zhuang L; Sarbassov dos D; Ma L; Gan B
Cancer Res; 2014 Mar; 74(6):1682-93. PubMed ID: 24448243
[TBL] [Abstract][Full Text] [Related]
12. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
[TBL] [Abstract][Full Text] [Related]
13. Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.
Shi H; Sun Y; He M; Yang X; Hamada M; Fukunaga T; Zhang X; Chang C
Oncogene; 2020 Jan; 39(3):530-545. PubMed ID: 31501521
[TBL] [Abstract][Full Text] [Related]
14. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
[TBL] [Abstract][Full Text] [Related]
15. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
16. The Adenosine A1 Receptor Antagonist DPCPX Inhibits Tumor Progression via the ERK/JNK Pathway in Renal Cell Carcinoma.
Zhou Y; Tong L; Chu X; Deng F; Tang J; Tang Y; Dai Y
Cell Physiol Biochem; 2017; 43(2):733-742. PubMed ID: 28950257
[TBL] [Abstract][Full Text] [Related]
17. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting prenylation augments chemotherapy efficacy in renal cell carcinoma through dual inhibition on mitochondrial respiration and glycolysis.
Huang J; Yang X; Peng X; Huang W
Biochem Biophys Res Commun; 2017 Nov; 493(2):921-927. PubMed ID: 28943437
[TBL] [Abstract][Full Text] [Related]
20. Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma.
Ruan H; Li S; Bao L; Zhang X
Oncogene; 2020 Sep; 39(38):6113-6128. PubMed ID: 32814829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]